It is recommended (Section 3) that a point in the center or in the central part of the Planning Target Volume (PTV) be selected as the ICRU Reference Point (Section 3.3.1), and that the dose at that point be defined as the ICRU Reference Dose (Section 3.3.2). It is mandatory to report the ICRU Reference Dose and to describe the dose variation by reporting also the maximum dose and the minimum dose in the PTV. In Section 3.3.1, general criteria are given for the selection of the ICRU Reference Point.
Among radiation oncologists and radiophysicists around the world, there is unanimous agreement regarding the need for uniformity in prescribing and reporting treatments. However, currently, many different methods are used (Hendricson, 1988) . Only one dose value is usually reported in the scientific literature, and such a single value is often used without further explanation as to its meaning. Dose variations are seldom reported, and reports based on, e.g., dose-volume histograms, can not be easily interpreted.
For prescribing and reporting ex;ternal beam therapy, many types of dose values are available (see Sections 2.4.3-2.4.7). Three commonly used methods for prescribing and reporting dose in external beam therapy will be analyzed. These three methods of reporting by stating one single dose value are: * dose in or at the central parts of the Planning Target Volume (PTV) and on or close to the central axis of the beam(s), * dose at the periphery of the PTV, e.g., isodose line or isodose surface (envelope) encompassing thePTV, * average dose in the PTV.
The relative merits of the three different methods are given in Table 111 .1. Other methods for reporting, e.g. , median dose, maximum dose, and modal dose are not dealt with here.
One of the first requirements for specification of doses for reporting is that the specification should be applicable to all clinical situations and all different levels of ambition for dose computation. The only dose parameter that meets this criterion is the dose in the central part of the PTV. This contrasts with the 64 situation with mInImUm and average dose to the PTV, where, if the dose calculation is to be significantly meaningful, it can only be done at level 3 and, to some extent, at level 2 (Section 3.3.4).
A second requirement for reporting the dose is that the dose value should be physically accurate. In an irradiated medium without any heterogeneity, it is obvious that the dose along the central axis can be calculated with good accuracy, since the beams are calibrated and also regularly checked at points along this axis. In points located off-axis or at the periphery, the uncertainty in the dose value will be much larger. This is caused by instability and heterogeneity of the dose distribution as well as the steep dose gradient close to the border of the beam. The dose at the periphery of the PTV thus cannot be determined in an accurate way and hence is unsatisfactory for comparison between different centers. The average dose can, however, be computed with good accuracy, since the off-axis variation is often averaged out inside the beam.
From a radiobiological point of view, the average dose to the cancer cell population is the parameter which is best correlated with tumor response, provided that the dose heterogeneity is not too large. However, in the CTV, the tumor cell density varies to a large extent and reaches, in principle, zero at its border. Therefore, the average dose to the corresponding PTV does not necessarily correspond to the average dose in the cancer cell population, and may thus lose part of its biological significance.
Isodose lines or isodose surfaces at the periphery of the PTV are used in some centres for dose specification (for prescription and for reporting). The objective with this approach is to ensure that all tissues containing tumor cells will receive at least the prescribed dose. In this situation, the dose value of the isodose line or isodose surface is identical to the minimum dose to the PTV. The dose at the periphery of the PTV thus can not be considered to be the most relevant single value to describe a treatment (even though it has to be estimated and reported in addition to the dose to the ICRU Reference Point). The 
Comments
Almost independent of type of dose computation (1-, 2-, or 3-D). Computer is needed. Limited physical accuracy. Dependent on dose computation method 0-, 2-, or 3-D). Computer is needed. Good physical accuracy. Dependent on dose computation method (1-, 2-, or 3-D) .
No freedom for selection.
Some freedom for selection. Furthermore, the selection can be influenced by the presentation of the values of the isodoses. No freedom for selection.
Almost independent. Dependent. Somewhat dependent.
Independent of the delineation ofthe PTV. Independent of method of patient data acquisition (1-, 2-, or 3-D). Can be used for all types of volumes. Delineation of the PTV may vary with different therapists, and the minimum dose then depends on the PTV. Dependent on type of patient data acquisition (1-, 2-, 3-D). Can be used for all types of volumes. Dependent on the delineation of the PTV. Dependent on method of patient data acquisition 0-, 2-, 3-D). Little significance if large dose variation in PTV.
Defined in a region where the tumor cell density usually is high.
Defined in a region with low or variable tumor cell density. Variation of tumor cell density from its maximum value down to zero. decision of the clinical safety margin is one of the most critical steps in radiotherapy. Consequently, the size and border of the CTV may vary considerably from one radiation oncologist to another for the same clinical situation, due to different opinions. Also, the selection of proper margins when defining the PTV may vary from therapist to therapist.
The dose at the central part of the PTV, along the central axes of the beams, must then be reported in all cases. It is the most representative single dose value for the PTV. However, in order to evaluate the total dose distribution in the PTV, the dose variation (maximum and minimum dose to the PTV) (Section 3.3.3) also have to be reported.
